Seroprevalence and Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Among Incarcerated Adult Men in Quebec, Canada, 2021

被引:9
|
作者
Kronfli, Nadine [1 ,2 ,3 ]
Dussault, Camille [1 ]
Maheu-Giroux, Mathieu [4 ]
Halavrezos, Alexandros [1 ]
Chalifoux, Sylvie [1 ]
Sherman, Jessica [1 ]
Park, Hyejin [1 ]
Del Balso, Lina [1 ]
Cheng, Matthew P. [2 ,5 ]
Poulin, Sebastien [6 ]
Cox, Joseph [1 ,2 ,3 ,4 ]
机构
[1] McGill Univ, Hlth Ctr, Res Inst, Ctr Outcomes Res & Evaluat, Montreal, PQ, Canada
[2] McGill Univ, Hlth Ctr, Dept Med, Div Infect Dis, Montreal, PQ, Canada
[3] McGill Univ, Hlth Ctr, Chron Viral Illness Serv, Montreal, PQ, Canada
[4] McGill Univ, Fac Med & Hlth Sci, Sch Populat & Global Hlth, Dept Epidemiol & Biostat, Montreal, PQ, Canada
[5] McGill Univ, Hlth Ctr, Div Med Microbiol, Dept Med, Montreal, PQ, Canada
[6] Ctr Integre Sante & Serv Sociaux Laurentides, St Jerome, PQ, Canada
关键词
SARS-CoV-2; seroprevalence; antibody; incarceration; prison; UNITED-STATES; COVID-19; SARS-COV-2; PRISONS; PEOPLE;
D O I
10.1093/cid/ciac031
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background People in prison are at increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We examined the seroprevalence of SARS-CoV-2 and associated carceral risk factors among incarcerated adult men in Quebec, Canada. Methods We conducted a cross-sectional seroprevalence study in 2021 across 3 provincial prisons, representing 45% of Quebec's incarcerated male provincial population. The primary outcome was SARS-CoV-2 antibody seropositivity (Roche Elecsys serology test). Participants completed self-administered questionnaires on sociodemographic, clinical, and carceral characteristics. The association of carceral variables with SARS-CoV-2 seropositivity was examined using Poisson regression models with robust standard errors. Crude and adjusted prevalence ratios (aPR) with 95% confidence intervals (95% CIs) were calculated. Results Between 19 January 2021 and 15 September 2021, 246 of 1100 (22%) recruited individuals tested positive across 3 prisons (range, 15%-27%). Seropositivity increased with time spent in prison since March 2020 (aPR, 2.17; 95% CI, 1.53-3.07 for "all" vs "little time"), employment during incarceration (aPR, 1.64; 95% CI, 1.28-2.11 vs not), shared meal consumption during incarceration ("with cellmates": aPR, 1.46; 95% CI, 1.08-1.97 vs "alone"; "with sector": aPR, 1.34; 95% CI, 1.03-1.74 vs "alone"), and incarceration post-prison outbreak (aPR, 2.32; 95% CI, 1.69-3.18 vs "pre-outbreak"). Conclusions The seroprevalence of SARS-CoV-2 among incarcerated individuals was high and varied among prisons. Several carceral factors were associated with seropositivity, underscoring the importance of decarceration and occupational safety measures, individual meal consumption, and enhanced infection prevention and control measures including vaccination during incarceration. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence was high among incarcerated adult men in Quebec, Canada. Several carceral factors were associated with seropositivity, underscoring decarceration and infection prevention and control measures such as vaccination in preventing future SARS-CoV-2 outbreaks.
引用
收藏
页码:E165 / E173
页数:9
相关论文
共 50 条
  • [21] Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Seoul, Korea
    Sim, Jiwoo
    Son, Euncheol
    Kwon, Minsu
    Hwang, Eun Jin
    Lee, Young Hwa
    Choe, Young June
    INFECTION AND CHEMOTHERAPY, 2024, 56 (02): : 204 - 212
  • [22] Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
    Kennedy, Joshua L.
    Forrest, J. Craig
    Young, Sean G.
    Amick, Benjamin
    Williams, Mark
    James, Laura
    Snowden, Jessica
    Cardenas, Victor M.
    Boothe, Danielle
    Kirkpatrick, Catherine
    Modi, Zeel
    Caid, Katherine
    Owens, Shana
    Kouassi, Marianne
    Mann, Ryan
    Putt, Claire
    Irish-Clardy, Katherine
    Macechko, Michael
    Brimberry, Ronald K.
    Nembhard, Wendy N.
    McElfish, Pearl A.
    Du, Ruofei
    Jin, Jing
    Zohoori, Namvar
    Kothari, Atul
    Hagrass, Hoda
    Olgaard, Ericka
    Boehme, Karl W.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (05):
  • [23] Prevalence of severe acute respiratory syndrome Coronavirus-2 among the young people and association between diabetes, hypertension, and severe acute respiratory syndrome Coronavirus-2
    Akter, Aklima
    Tabassum, Nafisa
    Rahman, Arifur
    BIOMEDICAL AND BIOTECHNOLOGY RESEARCH JOURNAL, 2021, 5 (02): : 134 - 138
  • [24] Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms
    Carreno, Juan Manuel
    Mendu, Damodara Rao
    Simon, Viviana
    Shariff, Masood A.
    Singh, Gagandeep
    Menon, Vidya
    Krammer, Florian
    ISCIENCE, 2021, 24 (09)
  • [25] Neuropathogenesis of severe acute respiratory syndrome coronavirus 2
    Patel, Payal B.
    Bearden, David
    CURRENT OPINION IN PEDIATRICS, 2021, 33 (06) : 597 - 602
  • [26] Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic
    Aquila, Isabella
    Sacco, Matteo Antonio
    Abenavoli, Ludovico
    Malara, Natalia
    Arena, Vincenzo
    Grassi, Simone
    Ausania, Francesco
    Boccuto, Luigi
    Ricci, Cristoforo
    Gratteri, Santo
    Oliva, Antonio
    Ricci, Pietrantonio
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2020, 144 (09) : 1048 - 1056
  • [27] Early Risk Factors for the Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Positivity in Patients With Coronavirus Disease 2019
    Lin, Aifen
    He, Ze-Bao
    Zhang, Sheng
    Zhang, Jian-Gang
    Zhang, Xia
    Yan, Wei-Hua
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (16) : 2061 - 2065
  • [28] Outcome of severe acute respiratory syndrome coronavirus 2 infection and risk factors for the development of pneumonia in patients with lymphoma
    Hong, H.
    Choi, S. M.
    Jeon, Y. W.
    SWISS MEDICAL WEEKLY, 2022, 152 : 12S - 13S
  • [29] Seroprevalence of Severe Acute Respiratory Syndrome-Coronavirus-2 Immunoglobulin M and Immunoglobulin G Antibodies among the Population of Koya University
    Blbas, Safia S. I.
    Ahmad, Hiwa A.
    Hawezy, Dawan J.
    Shawgery, Hemn
    Bahadin, Hersh N.
    ARO-THE SCIENTIFIC JOURNAL OF KOYA UNIVERSITY, 2021, 9 (02): : 51 - 57
  • [30] Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya
    Kagucia, E. Wangeci
    Gitonga, John N.
    Kalu, Catherine
    Ochomo, Eric
    Ochieng, Benard
    Kuya, Nickline
    Karani, Angela
    Nyagwange, James
    Karia, Boniface
    Mugo, Daisy
    Karanja, Henry K.
    Tuju, James
    Mutiso, Agnes
    Maroko, Hosea
    Okubi, Lucy
    Maitha, Eric
    Ajuck, Hossan
    Mukabi, David
    Moracha, Wycliffe
    Bulimu, David
    Andanje, Nelson
    Aman, Rashid
    Mwangangi, Mercy
    Amoth, Patrick
    Kasera, Kadondi
    Ng'ang'a, Wangari
    Nyaguara, Amek
    Voller, Shirine
    Otiende, Mark
    Bottomley, Christian
    Agoti, Charles N.
    Ochola-Oyier, Lynette, I
    Adetifa, Ifedayo M. O.
    Etyang, Anthony O.
    Gallagher, Katherine E.
    Uyoga, Sophie
    Barasa, Edwine
    Bejon, Philip
    Tsofa, Benjamin
    Agweyu, Ambrose
    Warimwe, George M.
    Scott, J. Anthony G.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (07):